Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383413 | 1.00 | TSHR (0.45) | TSHRNISCHENPP2NOTUMAR | |
| SCHEMBL11608 | 0.80 | TSHR (0.50) | TSHRENPP2NOTUMALDH1A1CA1 | |
| SCHEMBL29468918 | 0.80 | TSHR (0.50) | TSHRENPP2NOTUMALDH1A1CA1 | |
| SCHEMBL819145 | 0.79 | TSHR (0.59) | TSHRNISCHARALDH1A1CA1 | |
| SCHEMBL21143321 | 0.79 | TSHR (0.40) | TSHRENPP2NOTUMALDH1A1CA1 | |
| SCHEMBL7375093 | 0.79 | TSHR (0.40) | TSHRENPP2NOTUMALDH1A1CA1 | |
| SCHEMBL19785358 | 0.78 | TSHR (0.39) | TSHRENPP2NOTUMARPDK2 | |
| SCHEMBL29955943 | 0.78 | TSHR (0.39) | TSHRENPP2NOTUMARPDK2 | |
| SCHEMBL561951 | 0.78 | NOTUM (0.39) | TSHRENPP2NOTUMARALDH1A1 | |
| SCHEMBL18340951 | 0.78 | TSHR (0.39) | TSHRENPP2NOTUMALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663626-A1 | IMINE COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Bio Genuine (Shanghai) Biotech Co., Ltd (CN) | 2025-12-17 | — | — | EP | disclosed |
| EP-4620533-A2 | ANTAGONIST COMPOUNDS | Adorx therapeutics Limited (GB) | 2025-09-24 | — | — | EP | disclosed |
| US-20250270244-A1 | ORGANOMETALLIC COMPLEX, LIGHT-EMITTING MATERIAL FOR TOP EMISSION, LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, ELECTRONIC DEVICE, AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-08-28 | — | — | US | disclosed |
| EP-4188924-B1 | ANTAGONIST COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-06-18 | — | — | EP | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| US-12325716-B2 | Organometallic complex, light-emitting material for top emission, light-emitting device, light-emitting apparatus, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-06-10 | — | — | US | disclosed |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| EP-4548918-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250040336-A1 | Light-Emitting Device, Light-Emitting Apparatus, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO, LTD. (JP) | 2025-01-30 | — | — | US | disclosed |
| US-12120900-B2 | Light-emitting device, light-emitting apparatus, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-10-15 | — | — | US | disclosed |
| US-6849619-B2 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6699852-B2 | ANTISEROTONIN AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-02 | — | — | US | disclosed |
| EP-1343791-A2 | SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-21 | — | — | US | disclosed |
| CN-1370176-A | Subsstituted heterocycle fused gamma-carbolines | BRISTOL MYERS SQUIBB CO (US) | 2002-09-18 | — | — | CN | disclosed |
| WO-2002059129-A2 | SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | TSHR 305/4885NISCH 684/4885ENPP2 815/4885 |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | TSHR 305/4885NISCH 684/4885ENPP2 815/4885 |
| US-12325716-B2 | Organometallic complex, light-emitting material for top emission, light-emitting device, light-emitting apparatus, electronic device, and lighting device | CRY1, LIG4, LIG1 | TSHR 3621/4885NISCH 3000/4885ENPP2 4365/4885 |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | TSHR 565/4885NISCH 3720/4885ENPP2 1040/4885 |
| US-20250270244-A1 | ORGANOMETALLIC COMPLEX, LIGHT-EMITTING MATERIAL FOR TOP EMISSION, LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, ELECTRONIC DEVICE, AND LIGHTING DEVICE | CRY1, LIG4, LIG1 | TSHR 3621/4885NISCH 3000/4885ENPP2 4365/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | TSHR 4621/4885NISCH 3699/4885ENPP2 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.